Advancing Treatments for Bladder Cancer: Insights from ASCO GU 2024 - Episode 3

Recent Updates in Adjuvant Therapy for Muscle-Invasive Bladder Cancer

March 4, 2024

Elizabeth R. Plimack, MD, MS, FASCO, Neeraj Agarwal, MD, Matthew Milowsky, MD, FASCO, Evan Y. Yu, MD

Following an overview of the evolving adjuvant therapy space, Matthew Milowsky, MD, FASCO, reviews recent updates from ASCO GU 2024 in muscle-invasive bladder cancer.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer (MIBC)

EP. 2: Ongoing Research on Neoadjuvant Therapies in Muscle-Invasive Bladder Cancer

Now Viewing

EP. 3: Recent Updates in Adjuvant Therapy for Muscle-Invasive Bladder Cancer

EP. 4: Expert Insights on Updates in Adjuvant Therapy for Muscle-Invasive Bladder Cancer

EP. 5: Emerging Data in Metastatic Urothelial Carcinoma

EP. 6: Clinical Insights on Recent Data in Metastatic Urothelial Carcinoma

EP. 7: Cisplatin Eligibility and Maintenance Therapy in Metastatic Urothelial Carcinoma

EP. 8: Later-Line Therapies for Metastatic Urothelial Carcinoma

EP. 9: Treatment Sequencing Practices in Metastatic Urothelial Carcinoma

EP. 10: Exciting New Approaches in Metastatic Urothelial Carcinoma

EP. 11: Key Takeaways on Updates in Bladder Cancer